Consensus on Postoperative Recurrence Prediction of Non-small Cell Lung Cancer
Based on Molecular Markers.
10.3779/j.issn.1009-3419.2022.102.44
- Collective Name:Guangdong Association of Thoracic Diseases
- Publication Type:Journal Article
- Keywords:
Consensus;
Lung neoplasms;
Molecular markers;
Recurrence
- MeSH:
Humans;
Carcinoma, Non-Small-Cell Lung/surgery*;
Lung Neoplasms/surgery*;
Consensus;
Early Detection of Cancer;
Neoplasm Staging;
Neoplasm Recurrence, Local/genetics*
- From:
Chinese Journal of Lung Cancer
2022;25(10):701-714
- CountryChina
- Language:Chinese
-
Abstract:
Significant progress has been made in lung cancer screening, surgery, chemoradiation, targeted therapy, and immunotherapy recently. Surgical resection is the most important treatment for localized non-small cell lung cancer (NSCLC) so far, but there are still many patients who develop local recurrence or distant metastases within 5 years of surgery. Currently, the risk factors of recurrence in patients with NSCLC are mainly based on clinical and pathological features, which hardly identify patients at high risk of recurrence accurately. With the development of new detection technologies, a number of molecular markers that may have a predictive risk of recurrence in NSCLC have been discovered over the years. In order to summarize the molecular markers related to postoperative recurrence in NSCLC patients, we have formulated a consensus on the prediction of postoperative recurrence of NSCLC based on molecular markers. This consensus mainly focuses on the early stage NSCLC patients, discusses and summarizes the risk factors of disease recurrence from the molecular level. It is hoped that more and more valuable information can be provided for the management of patients, so as to provide more guidance for the perioperative management of the patients with early stage NSCLC in the future.
.
